- $965.07m
- $272.37m
- $682.16m
- 50
- 30
- 34
- 31
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 9.26 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.41 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -61.31% | ||
| Return on Equity | n/a | ||
| Operating Margin | -36.49% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 475.6 | 1,146.29 | 1,981.87 | 983.71 | 682.16 | 654.86 | 520.68 | 105.39% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | -54.84 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Directors
- James Young CHM (68)
- Stanley Erck PRE (73)
- James Kelly CFO (55)
- Gregory Glenn CEX (67)
- Rick Crowley COO
- Jill Hoyt CHO
- Troy Morgan EVP
- John Herrmann EVP (55)
- Filip Dubovsky EVP
- John Trizzino EVP (61)
- Frank Czworka SVP (47)
- Silvia Taylor SVP
- Marco Cacciuttolo SVP
- Madelyn Caltabiano SVP
- Nasir Egal SVP
- Denny Kim SVP
- Raburn Mallory SVP
- Brian Rosen SVP
- Gale Smith SVP
- Henrietta Ukwu SVP
- Brian Webb SVP
- Rajiv Modi DRC (60)
- Gregg Alton IND (55)
- Richard Douglas IND (68)
- Gary Evans IND (63)
- Rachel King IND (61)
- Margaret Mcglynn IND (61)
- Michael Mcmanus IND (78)
- David Mott IND (55)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 18th, 1987
- Public Since
- May 16th, 1973
- No. of Employees
- 952
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 160,844,197
- Address
- 700 Quince Orchard Road, GAITHERSBURG, 20878
- Web
- https://www.novavax.com/?locale=US
- Phone
- +1 2402682000
- Auditors
- Ernst & Young LLC
Upcoming Events for NVAX
Novavax Inc Annual Shareholders Meeting
Q2 2025 Novavax Inc Earnings Release
Similar to NVAX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Novavax share price?
As of Today at 22:21 UTC, shares in Novavax are trading at $6.00. This share price information is delayed by 15 minutes.
How has the Novavax share price performed this year?
Shares in Novavax last closed at $6.00 and the price had moved by +54.24% over the past 365 days. In terms of relative price strength the Novavax share price has outperformed the S&P500 Index by +45.03% over the past year.
What are the analyst and broker recommendations for Novavax?
The overall consensus recommendation for Novavax is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Novavax dividend yield?
Novavax does not currently pay a dividend.
Does Novavax pay a dividend?
Novavax does not currently pay a dividend.
When does Novavax next pay dividends?
Novavax does not currently pay a dividend.
How do I buy Novavax shares?
To buy shares in Novavax you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Novavax?
As of the previous close price of $6.00, shares in Novavax had a market capitalisation of $965.07m.
Where are Novavax shares listed?
Here are the trading details for Novavax:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: NVAX
What kind of share is Novavax?
Based on an overall assessment of its quality, value and momentum Novavax is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Novavax share price forecast for 2025?
The analyst consensus target price for shares in Novavax is $17.33. That is 188.83% above the last closing price of $6.00.
Analysts covering Novavax currently have a consensus Earnings Per Share (EPS) forecast of $0.78 for the next financial year.
Find out moreWhat is the trend in the Novavax share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Novavax. Over the past six months, its share price has underperformed the S&P500 Index by -34.69%.
As of the last closing price of $6.00, shares in Novavax were trading -40.19% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Novavax PE Ratio?
The Novavax PE ratio based on its reported earnings over the past 12 months is 9.26. The shares last closed at $6.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Novavax?
Novavax's management team is headed by:
- James Young - CHM
- Stanley Erck - PRE
- James Kelly - CFO
- Gregory Glenn - CEX
- Rick Crowley - COO
- Jill Hoyt - CHO
- Troy Morgan - EVP
- John Herrmann - EVP
- Filip Dubovsky - EVP
- John Trizzino - EVP
- Frank Czworka - SVP
- Silvia Taylor - SVP
- Marco Cacciuttolo - SVP
- Madelyn Caltabiano - SVP
- Nasir Egal - SVP
- Denny Kim - SVP
- Raburn Mallory - SVP
- Brian Rosen - SVP
- Gale Smith - SVP
- Henrietta Ukwu - SVP
- Brian Webb - SVP
- Rajiv Modi - DRC
- Gregg Alton - IND
- Richard Douglas - IND
- Gary Evans - IND
- Rachel King - IND
- Margaret Mcglynn - IND
- Michael Mcmanus - IND
- David Mott - IND